Develop Protocols News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NeonMind Biosciences Inc: NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity
NeonMind Biosciences Inc. (CSE: NEON) (
NeonMind ), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia where he was previously Professor of Internal Medicine, and he has extensive experience in the design of clinical trials for treatments for eating disorders. He has also been appointed to NeonMind s Board of Advisors. ....

United Kingdom , British Columbia , C Laird Birmingham , Member Of The Brain Research Centre , Exvera Communications Inc , Centre For Health Evaluation , World Health Organization , Edge Communications , Woodstone Residential Treatment Centre For Eating Disorders , British Columbia Newsfile Corp , University Of British Columbia , Neonmind Biosciences Inc , Canadian Securities Exchange , Outcome Sciences , Mind Biosciences , Internal Medicine , Mind Engages , Develop Protocols , Trial Using Psilocybin , General Internal Medicine , Obesity Clinic , Disorders Epidemiology Project , Health Evaluation , Eating Disorders , Medical Director , Woodstone Residential Treatment Centre ,